TNFRSF10A and neoplasm: DR4 and DR5 levels were examined by immunohistochemistry (IHC) in tumor tissues [20,23,116,117,118,119,126,131,133,146,147,148], although the levels of DR4 and DR5 expression have not always correlated with response in the preclinical setting [30].